CardioComm Solutions Inc (TSX-Venture:EKG) got pulses racing Monday, as the provider of consumer heart monitoring and electrocardiogram acquisition and management software solutions confirmed today progress on a royalty licensng agreement with California-based Biotricty Inc.
A news release issued this morning revealed the royalty payment phase became active following confirmation that all necessary clearance and software development pre-conditions have been achieved.
EKG is seeking additional partnerships with new device manufacturers that will allow them access to the Company's trusted ECG software, thus making product acceptance by consumers, physicians and patients that much quicker.
Shares grew half a cent, or 9.1%, by midday Monday to six cents.
